CSL Hisse

CSL Net Borç

Delisted·19 Haz 2026

CSL (CSL.AX) öğesinin Net Borç değeri 8 Ağu 2026 itibarıyla 9,34 Md USD dir. Önceki yılda, Net Borç 10,53 Md USD idi — -11,26% (daha düşük) bir değişiklik.

Net Borç

9,34 MdUSD

YoY

-11,26%

Son güncelleme:

CSL öğesinin Net Borç değeri 2026 9,34 Md USD dir. CSL öğesinin Net Borç değeri 2025 10,53 Md USD idi. %-11,26 daha düşük önceki yıla kıyasla azalmaktadır.
Access this data via the Eulerpool API

CSL Hisse senedi analizi

CSL ne yapar? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL, Eulerpool'daki en popüler şirketlerden biridir.

CSL hisse senedi hakkında sık sorulan sorular

CSL şirketinin Net Borç değeri 2026 yılında 9,34 Md USD.

CSL öğesinin Net Borç değeri 10,53 Md USD değerinden 9,34 Md USD değerine değişmiş ve bu %-11,26 değişimi temsil etmektedir. Değer önceki yıldan daha düşük dir.

Eulerpool'da Net Borç öğesinin CSL değerinin 2006'dan itibaren tam tarihsel gelişimini bulabilirsiniz — yıllık değerler, grafikler ve ayrıntılı analiz ile.

Net borç, toplam borcun nakit ve nakit benzeri varlıklarla azaltılmasıdır. Mevcut likit kaynakları dikkate aldıktan sonra fiili borç yükünü gösterir.

Net Borç'nin USD, yatırımcılar için kilit bir faktördür. Bu metrikte yapılan değişiklikler temel faktörlerin iyileşmesini veya kötüleşmesini gösterebilir ve hisse senedi fiyatını doğrudan etkiler. Eulerpool'da Net Borç'nin CSL değerini tarihsel olarak ve gerçek zamanlı olarak takip edebilirsiniz.

Access this data via the Eulerpool API

Bilançolar — CSL

Tüm Kilit Metrikler — CSL